Impact on antitumor response using a new adjuvant preparation as a component of a human papillomavirus type 16 therapeutic vaccine candidate

2019/05/30 by Milaid Granadillo, Aileen Batte, Alain B. Alfonso +10 · 5 citations
Immunology and Microbiology · Medicine · Biochemistry, Genetics and Molecular Biology · #Immunotherapy and Immune Responses #Cervical Cancer and HPV Research #vaccines and immunoinformatics approaches

paper · doi:10.1016/j.vaccine.2019.05.060

Citations

• A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice

Cited by

• Development of HPV nanovaccine candidate based on IL-15-E7 fusion protein encapsulated in silk-fibroin nanoparticles
• FLT3L and granulocyte macrophage colony-stimulating factor enhance the anti-tumor and immune effects of an HPV16 E6/E7 vaccine. [europepmc]
• Therapeutic Vaccines for HPV-Associated Malignancies. [europepmc]
• VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. [europepmc]
• Current status and future directions for the development of human papillomavirus vaccines. [europepmc]